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Abstract
Background: Improvement of health-related quality of life (HRQOL) is an important goal in preventive cardiology.
HRQOL is also related to depressive symptoms, which represent a common co-morbidity and risk factor in patients
with an acute coronary syndrome (ACS). Comprehensive nurse-coordinated prevention programmes (NCPP) in
secondary care have been shown to reduce cardiovascular risk, however their effects on HRQOL and depressive
symptoms have not been evaluated. We therefore investigated HRQOL and depressive symptoms in a secondary
analysis in the RESPONSE trial, evaluating the effect of a NCPP on cardiovascular risk.
Methods: RESPONSE was a multicentre (n = 11) randomised controlled trial in ACS-patients in secondary and
tertiary healthcare settings evaluating a NCPP. The intervention consisted of four outpatient nurse clinic visits in the
first 6 months after the index event, focusing on healthy lifestyles, biometric risk factors and medication adherence,
in addition to usual care. The control group received usual care only. The outcome was change in HRQOL as
measured by the MacNew questionnaire and change in depressive symptoms as measured by Beck’s Depression
Inventory (BDI) questionnaire at 12-months follow-up relative to baseline.
Results: Of 754 patients randomised, 615 were analysed for HRQOL; 120 for depressive symptoms. At baseline, HRQOL
was 5.17 (SD 1.09) and 5.20 (SD1.04) (scale range 1.0 to 7.0) in the intervention and control group, respectively. At
12 months follow-up, HRQOL increased by 0.57 (SD 0.89) in the intervention group as compared with 0.42 (SD 0.90) in
the control group (p = 0.03). This increase was observed across all relevant subscales. The BDI decreased by 1.9 in the
intervention group as compared with 0.03 in the control group (p = 0.03) (scale range 1.0 to 63).
Conclusion: Participation in a NCPP is associated with a modest but statistically significant increase in HRQOL, and a
decrease of depressive symptoms, both of which are highly relevant to patients. A reduction in depressive symptoms
may in addition contribute to a reduction in the overall risk of recurrent events.
Trial registration: Dutch trials register: NTR1290. Registered 24 April 2008.
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Background
Patients with established coronary artery disease are at
high risk of recurrent coronary events and mortality. Ef-
fective secondary prevention, including optimal medical
therapy and lifestyle interventions (i.e. smoking cessa-
tion, healthy diet, weight loss/maintenance and regular
exercise) can significantly reduce this risk [1, 2]. Nurses
acting as disease managers have been demonstrated to be
effective in reducing cardiovascular risk in several preven-
tion programmes [3–6]. Therefore the European guideline
on cardiovascular disease prevention and the World
Health Organisation recommend nurse-coordinated pre-
vention programmes (NCPP) to be integrated into health-
care systems [2, 7]. Such programmes are increasingly
being implemented in clinical practice. We have previ-
ously shown that participation in a NCPP as part of the
RESPONSE (Randomised Evaluation of Secondary Pre-
vention by Outpatient Nurse SpEcialist) trial leads to a re-
duction in cardiovascular risk and a reduction of hospital
admissions. This trial included patients with an acute
coronary syndrome (ACS); most of who had multiple risk
factors, including a high prevalence of lifestyle related risk
factors. In short, the intervention group received nurse-
coordinated care on top of usual care, while the control
group received usual care only. We found that a NCPP
improves risk factor control after 1 year. However,
lifestyle-related risk factors, such as smoking and over-
weight, remained largely unchanged, with the exception of
physical activity, where an improvement was observed (al-
beit self-reported) [7].
Health related quality of life (HRQOL), including emo-
tional, physical and social well-being, is an important
goal in preventive cardiology, in addition to optimal risk
factor control [8]. Patients with an unhealthy lifestyle
have been shown to have a lower HRQOL [9]. Neverthe-
less, lifestyle interventions have been shown to improve
HRQOL [10]. Furthermore, HRQOL is influenced by a
wide range of factors, such as patient characteristics and
emotions, but also by factors as the quality of informa-
tion and communication, factors which are targeted by
NCPPs.
Furthermore, HRQOL is related to depressive symp-
toms, and depression is a common comorbidity among
ACS-patients, with an incidence in the year after an
acute myocardial infarction ranging from 10 to 30 % per
year [11–13]. Major and minor depressions have been
shown to be independent risk factors for cardiovascular
mortality [14, 15]. Recently the American Heart Asso-
ciation listed depression as a risk factor for adverse
medical outcomes in ACS-patients [15]. Depression is
also associated with a higher prevalence of unhealthy
behaviour, such as smoking and a sedentary lifestyle,
and depression per se may also contribute to poorer
cardiovascular outcomes [16–18].
Participation in a NCPP may improve HRQOL or de-
pressive symptoms, resulting from continued care and
attention to the patient’s personal situation. However, as
NCPPs usually focus on risk factors, there may poten-
tially be a detrimental effect on HRQOL or depressive
symptoms if the attempted lifestyle changes are unsuc-
cessful or if the effort to change one’s lifestyle is too
arduous. For individual patients, smoking cessation,
weight loss and diets, and limitations in alcohol intake
may be perceived as a limitation of HRQOL, while the
preventive effects (if successful) are not directly experi-
enced (i.e. reduction of risk) [19, 20]. Therefore it is
important to investigate whether a NCPP impacts on
HRQOL and on depressive symptoms in a groups of ACS-
patients and a high prevalence of CVD risk factors, in-
cluding lifestyle related risk factors. We therefore aimed
to investigate the change in HRQOL and depressive
symptoms in the RESPONSE-population.
Methods
Study design
The RESPONSE trial was a multicentre, randomised
controlled trial conducted in 11 hospitals in the
Netherlands from June 2006 to July 2009. The study was
designed to evaluate the impact of a practical, hospital-
based NCPP on top of usual care in patients hospitalised
for an ACS. The RESPONSE trial has been described in




Eligible patients were 18–80 years of age, admitted for
ACS (ST-segment myocardial infarction, non-ST-segment
elevation myocardial infarction or unstable angina pec-
toris) The window of inclusion was up to 8 weeks after
the date of discharge ACS. Exclusion criteria were: 1)
unable to visit outpatient clinic 2) not available for
follow-up 3) surgery or percutaneous coronary inter-
vention expected within 8 weeks after inclusion 4) lim-
ited life expectancy (≤2 years) 5) previously enrolled in
a NCPP, 6) congestive heart failure New York Heart As-
sociation class III or IV.
Patients were screened during or shortly after hospital-
isation by their treating physician or a trained nurse. Pa-
tients were randomised using an online randomisation
protocol. The online randomisation protocol consisted
of a pre-generated block-stratified randomisation proto-
col (www.responsestudie.nl). Study personnel entered
patients’ initials, date of birth and gender, and participat-
ing individuals were assigned a study identification num-
ber along with their allocation to either the intervention
or control group. The randomisation protocol was de-
signed and generated by an independent third party;
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study personnel had no influence on the randomisation
process [7, 21]. The Academic Medical Center Ethical
Review Board and institutional committees on human
research of all recruiting hospitals approved the protocol
and informed consent was obtained from all patients.
Intervention group
Patients randomised to the intervention group were
invited to attend the NCPP in addition to usual care.
This programme included 4 outpatient clinic visits to a
cardiovascular nurse during the first 6 months after in-
clusion. Between 6 months and 1 year there were no
visits to the NCPP.
The NCPP was developed based on national and inter-
national guidelines, focusing on (1) healthy lifestyles, (2)
biometric risk factors, and (3) medication adherence [1,
2, 22]. Each visit was structured by pre-defined topics,
including smoking status, dietary status, level of physical
activity, and medication use. Smoking was defined as
smoking prior to the index event, physically inactive was
defined as less than 30 min of moderate physical activity
per day for at least 5 days per week [2]. The nurse pro-
vided advice on lifestyle and gave individual counselling
and education as appropriate. During each visit weight,
waist circumference, blood pressure, lipid profile (total
cholesterol, LDL-cholesterol, HDL-cholesterol, triglycer-
ide), fasting glucose and HbA1c were measured. For
each variable, a target value was defined. When this tar-
get value was not reached, medication could be changed
(in collaboration with the treating physician), or the pa-
tient could be referred to another health professional, in
addition to counselling and advice.
Study nurses were all registered nurses with a 4-year
bachelor’s degree, and competent in cardiac care. As part
of the study, nurses were trained during a 3 day course
in the principles of motivational interviewing, a method
often utilised to achieve lifestyle changes [23].
Control group
Patients randomised to the control group received
usual care only, including visits to their treating cardi-
ologists and other relevant specialists, and were offered
cardiovascular rehabilitation according to national
guidelines [22].
Data collection
For our analysis, we used data collected at baseline and
12 months follow-up. Demographics (gender, educa-
tional status, work status, civil status and ethnicity), and
cardiovascular risk factors (cardiovascular history, smok-
ing status prior to index event, dietary status, level of
physical activity and medication) were self-reported.
Weight, height, waist circumferences, and blood pressure
were objectively measured. Fasting blood samples were
analysed for lipid profiles, glucose and HbA1c.
Health-related Quality of Life (HRQOL)
We used the MacNew Heart Disease Heart-related
Quality of Life questionnaire (MacNew) to measure
quality of life. MacNew is a self-administered instrument
consisting 27 items related to three domains of HRQOL:
emotional, physical and social quality of life. Each item
is rated on a 7–point Likert scale, where ‘1’ indicates
poor HRQOL and ‘7’ indicates good HRQOL. A total
score is calculated by taking the average of the score on
each item. Missing items do not contribute to the total
score, and if more than 4 items were missing a total
score is not calculated. An emotional subscale score is
calculated by 14 items (questions 1, 2, 3, 4, 5, 6, 7, 8, 10,
15 and 18), a physical subscale score by 13 items (ques-
tions 2, 6, 9, 11, 14, 16, 17, 19, 20 and 21), and a social
subscale score by 13 items (questions 11, 12, 13, 15, 22,
23 and 27). The MacNew has been shown to be a
valid, reliable and responsive questionnaire for pa-
tients diagnosed with myocardial infarction and an-
gina pectoris [24].
Depression screening
Data collection on depressive symptoms was added in a
subset of patients (included in 6 hospitals) after initi-
ation of the main study from September 2008 till July
2009 (protocol addendum). For depression screening, we
used the Beck Depression Inventory (BDI). The BDI is a
21 item self-report questionnaire, developed to assess
the presence and severity of depressive symptoms. Each
item is rated on a 0–3 scale. A total score is presented
as the sum of all items. The BDI is a reliable and vali-
dated measure of depressive symptomatology [25]. A
BDI score ≥ 10 indicates at least mild to moderate symp-
toms of depression and has been associated with poor
prognosis in patients with myocardial infarction [14]. For
our analysis, patients with a BDI score higher or equal to
10 were classified as depressed, and patients with a BDI
score lower than 10 were classified as non-depressed.
Study outcomes
The impact of the NCPP on HRQOL was measured as
the change in mean score of the MacNew questionnaire
between baseline and 12 months, comparing the inter-
vention group with the control group. The impact of the
NCPP on depressive symptoms was similarly measured
in a subgroup using the BDI. Both outcomes were sec-
ondary outcomes of the RESPONSE trial.
Statistical methods
Continuous variables with a normal distribution were
presented as mean and standard deviation (SD);
Jørstad et al. BMC Cardiovascular Disorders  (2016) 16:144 Page 3 of 9
categorical variables were presented as a number and
percentage. Comparisons between groups for continuous
data were analysed by independent samples t-tests or
Mann Whitney U-tests, categorical data by χ2 tests or
Fisher’s exact tests, as appropriate. The effect of time
and group on the Macnew score was analysed by an ana-
lysis of variance (ANOVA) with repeated measures. SPSS
statistics version 22.0 was used for all statistical analyses.
Results
A total of 1711 patients were screened for eligibility, and
754 patients were included and randomised in the
RESPONSE study; of those 710 (94 %) patients attended
12 months follow up. For the present analyses, we in-
cluded 615 (87 %) patients with complete MacNew
questionnaires at baseline and 12 months (308 in the
intervention group and 307 in the control group) (Fig. 1).
Patients who did not have complete questionnaires were
younger, less educated, unmarried or single, and had less
peripheral artery disease. Of these 615 patients, 120
(20 %) patients had complete BDI-data at baseline and
12 months.
Patient characteristics are presented in Table 1. The
mean age was 58 years, and 20 % of the patients were fe-
male. The majority (73 %) of the study population had
no known previous cardiovascular disease before admis-
sion for an ACS. In total, 44 % of the patients were
current smokers, more than 70 % had a BMI > 25 kg/m2,
and 49 % were physically inactive. Characteristics of the
patients screened for depressive symptoms were compar-
able with the total group. At baseline the BDI score was
8.1 (SD 7.2) in the intervention group and 6.1 (SD 5.1) in
the control group. Fifteen (28 %) patients were depressed
in the intervention group and 14 (21 %) patients were de-
pressed in the control group (BDI >10). There were no
significant differences in baseline characteristics between
the two groups.
Table 2 presents the scores and the changes in Mac-
New between baseline and 12 months follow-up.
HRQOL improved in both groups. There was a slight
but statistically significant greater improvement in Mac-
New scores at 12 months in favour of the intervention
group [Intervention +0.57 (SD 0.89) vs. control +0.42
(SD 0.90) p = 0.03]. This improvement was consistent
across all three dimensions of the questionnaire (emo-
tional, physical and social). The absolute difference in
mean change between the intervention and control
group was 0.15 (95 % CI 0.02–0.29 p = 0.03). No inter-
vention effect was seen with repeated measurements
ANOVA (p = 0.55), although the effects of time and the
interaction between time and group, were significant
(p < 0.001 and p = 0.03, respectively).
In patients with depression screening, the intervention
group showed a decrease of 1.9 points as compared with
Fig. 1 Study flowchart
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0.03 points in the control group (p = 0.03). The mean dif-
ference between the intervention and the control group
was −1.84 points [(95 % C.I. -3.45 to −0.20) p = 0.03]. At
12 months, 12 patients in the intervention group were de-
pressed as compared to 11 in the control group (p = ns).
Discussion
The main finding of our study is that participation in a
NCPP leads to an increase in HRQOL on top of im-
proved risk factor control in patients who have been
hospitalised for an ACS. This increase in HRQOL was
seen across all the emotional, physical and socials sub-
scales. Furthermore, a NCPP contributes to a reduction
in depressive symptoms in ACS patients. However, there
was no difference in the number of depressed patients
between the intervention and control group based on a
binary definition.
In addition to morbidity and mortality outcomes,
HRQOL plays an important role in treatment strategies.
A consensus statement from the Society for Cardiovas-
cular Angiography and Interventions advocates that
HRQOL outcomes should be measured in clinical trials
and guidelines [26]. In line with this, our study reports
the HRQOL outcomes from a large, randomised con-
trolled trial investigating the effect of such a programme
on cardiovascular risk factors.
Several studies in patients with coronary artery disease
have shown that HRQOL improves after treatment in
patients with coronary artery disease undergoing a
percutaneous coronary intervention, coronary artery by-
pass grafting or treated with optimal medical therapy
[27–29]. In our study, revascularisation rates in both
groups were comparable. Patients randomised to the
intervention group received greater emphasis on im-
provement of risk profiles through adherence to medica-
tion and changing unhealthy lifestyles. Usual care, as
provided in both groups, included visits to cardiologists,
general practitioners and other health care personnel,
Table 1 Baseline characteristics
Included in HRQOL analysis Included in depression analysis
Intervention Control Intervention Control
n = 308 n = 307 n = 54 n = 66
Demographics
Age (years) 57.7 (9.5) 58.2 (9.7) 57.3 (9.3) 58.1 (10.0)
Female 63 (21 %) 63 (21 %) 12 (22 %) 15 (23 %)
Caucasian 282 (92 %) 281 (92 %) 49 (91 %) 62 (94 %)
Higher education (>8 years) 69 (22 %) 65 (21 %) 11 (20 %) 12 (18 %)
Employed (fulltime or part-time) 162 (53 %) 171 (56 %) 32 (60 %) 37 (56 %)
Married/cohabiting 250 (81 %) 257 (84 %) 42 (84 %) 57 (88 %)
Previous vascular disease
Myocardial infarction 51 (17 %) 54 (18 %) 10 (19 %) 10 (15 %)
Percutaneous coronary intervention 41 (13 %) 46 (15 %) 6 (11 %) 6 (9 %)
Coronary artery bypass surgery 14 (5 %) 17 (6 %) 5 (9 %) 3 (5 %)
Stroke 12 (4 %) 7 (2 %) 0 (0 %) 0 (0 %)
Peripheral artery disease 18 (6 %) 22 (7 %) 6 (11 %) 7 (11 %)
No known previous cardiovascular disease 224 (73 %) 222 (73 %) 37 (69 %) 52 (80 %)
Cardiovascular risk factors
Positive family history 179 (58 %) 187 (61 %) 30 (56 %) 40 (62 %)
Diagnosed diabetes mellitus 42 (14 %) 42 (14 %) 6 (11 %) 8 (12 %)
Dyslipidaemia before hospital admission 214 (70 %) 218 (71 %) 35 (65 %) 42 (64 %)
Hypertension before hospital admission 120 (39 %) 107 (35 %) 19 (35 %) 22 (33 %)
Current smoking 142 (46 %) 126 (41 %) 27 (50 %) 26 (39 %)
Overweight (BMI > 25) 241 (78 %) 219 (71 %) 44 (82 %) 48 (73 %)
Physically inactive 155 (50 %) 149 (49 %) 24 (44 %) 32 (49 %)
Depression parameters
BDI score 8.1 (7.2) 6.1 (5.1)
BDI≥ 10 15 (28 %) 14 (21 %)
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Table 2 Change in MacNew score (HRQOL) from baseline to follow up
Baseline 12 months Change from baseline to 12 months
Intervention Control Intervention Control Intervention Control





Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean Mean Lower Upper p-value
MacNew total 5.17 (1.09) 5.20 (1.04) 5.74 (0.94) 5.62 (1.07) 0.57 0.42 0.15 0.07 0.02 0.29 0.03
Emotional subscale 5.04 (1.22) 5.03 (1.15) 5.56 (1.05) 5.40 (1.12) 0.51 0.37 0.15 0.08 −0.12 0.30 0.07
Physical subscale 5.01 (1.19) 5.07 (1.15) 5.65 (1.08) 5.54 (1.18) 0.64 0.46 0.18 0.08 0.02 0.34 0.03













and there were no restrictions in either group as to partici-
pation in cardiac rehabilitation programmes. Accordingly,
the observed improvement in HRQOL was achieved
against a background of a high level of usual care, and with
excellent adherence to medication in both groups [21].
Clinically meaningful changes in the total score of the
MacNew have been reported to be in the magnitude of
0.5, similar to our results [30]. Although both groups
showed improvement in quality of life, the intervention
group improved more than the control group. Potential
explanations for this improvement include more individ-
ual attention from the nurses, and their ability to re-
spond to individual patient’s needs, as well as providing
better information.
In the EuroAspire III survey (2006–2007), conducted
in 8745 patients with coronary artery disease in 22 Euro-
pean countries, HRQOL was shown to be higher in pa-
tients adopting healthier lifestyles [31]. However, the
EuroAspire III survey was designed as a cross-sectional
study, and the direction of the association between
HRQOL and lifestyle is uncertain. Adding to their obser-
vations, our study shows prospectively that attending an
NCPP (on top of usual care) improves both medication
adherence and lifestyle components and leads to a
greater improvement in HRQOL than usual care alone.
Murchie et al. (2004) investigated the effect of a NCPP
on quality of life (QOL) as measured by Short-Form 36
(SF-36). At 12-months follow-up, they showed a signifi-
cant improvement in 5 of 8 domains of SF-36, compar-
able with our findings [32]. However, our NCPP took
place in a hospital setting and, by comparison, we in-
cluded younger patients (58 years vs 66 years) with a
more recent coronary event. Furthermore, our measure
of interest was HRQOL as opposed to generic QOL. In
a cluster-randomised trial in primary practices, Khunti
et al. (2007) found a slight increase in QOL (SF36) in pa-
tients with coronary heart disease attending specialist
nurse managers as compared with usual care [33]. This
increase reached statistical significance in the domains
of physical functioning, general health, vitality, social
functioning and mental health. This study population
consisted mainly of chronic patients, and the interven-
tion was delivered in the primary practice.
Consistent with our findings, a meta-analysis by Ekers
et al. showed that nurse-delivered collaborative care is an
effective treatment for depression in patients with differ-
ent chronic health problems, including in coronary heart
disease. However, studies were included with nurse inter-
ventions specifically targeting depression, where nurses re-
ceived brief periods of training for this purpose [34]. In
our study, nurses received training in motivational inter-
viewing and secondary prevention, but not specifically for
depression treatment, as depression treatment was not a
pre-specified target in our study. Possibly, the nurse and
the extra attention and care received by patients visiting a
NCPP have, on their own, a modestly positive effect on
depressive symptoms. Furthermore, while the mean de-
crease in BDI was greater in the intervention group as
compared with the control group, this did not change the
prevalence of the number of depressed patients at
12 months, with 12 (22 %) patients in the intervention
group and 11 (17 %) patients in the control group having
a BDI > 10 after 1 year.
Strengths and limitations
There are several strengths to our study. First, we assessed
HRQOL in a large, contemporary randomised multicentre
trial with a well-defined trial population. Second, the
NCPP investigated in the trial was a practical intervention
with clearly defined intervention components, facilitating
future implementation of comparable programmes. Fi-
nally, complete questionnaires on HRQOL were available
in the majority of patients, making selection bias unlikely.
Some limitations should be considered when interpret-
ing our results. First, we did not collect data on systolic
left ventricular (dys) function. However, no patients in
our trial had severe, symptomatic heart failure, as we ex-
cluded all patients with heart failure NYHA class III or
IV. Only 6 patients (in the control group) were hospita-
lised for congestive heart failure during follow-up, mak-
ing congestive heart failure unlikely as a cause for the
slight difference in HRQOL observed between the
groups [7]. Second, we excluded patients >80 years of
age. While secondary prevention should always be con-
sidered in the context of life expectancy, improvements
in HRQOL would likely be of value in elderly and frail
patients. While it is conceivable that an increase in
HRQOL may be observed in patients older than in-
cluded in our trial, we cannot infer this from our data.
Additional factors, such comorbidity and frailty should
be taken into account when evaluating comparable inter-
ventions in these populations [35, 36]. Third, our trial
included a slightly lower proportion of women as com-
pared with other national and international surveys. In
the European Action on Secondary and Primary Preven-
tion by Intervention to Reduce Events (EUROASPIRE)
III survey, performed in 22 countries in Europe (includ-
ing the Netherlands), 27 % of participants were women
[37]. Fourth, we collected data about depression in a
small sample, as this component of the study was added
to the protocol after initiation of the main trial. Al-
though only a modest number of patients were screened
for depressive symptoms, we observed a small but sig-
nificant difference between the groups.
Conclusion
Our study suggests that participation in a nurse-
coordinated prevention programme with four outpatient
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clinic visits in addition to usual care leads to a small but
significant improvement in HRQOL in patients with an
ACS. This improvement was seen across the emotional,
physical and social dimensions of HRQOL. In addition
to the effect on HRQOL, the NCPP was found to reduce
depressive symptoms in these patients. In conclusion,
our study shows that a NCPP has a favourable effect on
HRQOL and depressive symptoms in patients who have
been hospitalised for an ACS.
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